Evidence map›Paper›PMID 25148404›Full record

ArticlePloS one2014

Modified extracorporeal photopheresis with cells from a healthy donor for acute graft-versus-host disease in a mouse model.

Holger Budde, Susanne Kolb, Laura Salinas Tejedor, Gerald Wulf, Holger M Reichardt, Joachim Riggert, Tobias J Legler

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  5. Review
  6. Review
  7. CD11cClinical and experimental immunology · 2021
    Article
  8. Review
  9. Article
  10. Central-European journal of immunology · 2017
    Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Holger BuddeDepartment of Transfusion Medicine, University Medical Center Göttingen, Göttingen, Germany.
Susanne KolbDepartment of Transfusion Medicine, University Medical Center Göttingen, Göttingen, Germany.
Laura Salinas TejedorDepartment of Transfusion Medicine, University Medical Center Göttingen, Göttingen, Germany.
Gerald WulfDepartment of Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany.
Holger M ReichardtInstitute for Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany.
Joachim RiggertDepartment of Transfusion Medicine, University Medical Center Göttingen, Göttingen, Germany.
Tobias J LeglerDepartment of Transfusion Medicine, University Medical Center Göttingen, Göttingen, Germany.
University of Göttingen · DEUniversitätsmedizin Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGraft-versus-host disease (GvHD) is a major challenge after hematopoietic stem cell transplantation but treatment options for patients are still limited. In many cases first-line treatment with glucocorticoids is not successful. Among second-line therapies the extracorporeal photopheresis (ECP) is frequently performed, due to induction of selective tolerance instead of general immunosuppression. However, for some patients with severe acute GvHD the leukapheresis step of the ECP procedure is physically exhausting and limits the number of ECP cycles.

methodsWe hypothesized that leukocytes from healthy cell donors could be used as a replacement for ECP leukocytes gained from the GvHD patient. For this purpose we used a well established mouse model of acute GvHD. The ECP therapy was based on cells with the genetic background of the initial donor of the stem cell transplantation. As a precondition we developed a protocol representing conventional ECP in mice equivalent to clinical used ECP setup.

resultsWe could demonstrate that conventional, clinically derived ECP setup is able to alleviate acute GvHD. By using leukocytes obtained from healthy mice with the bone marrow donor's genetic background we could not observe a statistically significant therapeutic effect.

conclusionsConventional human ECP setup is effective in the mouse model of severe acute GvHD. In addition we could not prove that ECP cells from healthy mice with bone marrow donor's genetic background are as effective as ECP cells derived from GvHD mice. Based on our findings, new questions arise for further studies, in which the cellular characteristics for ECP mediated immune tolerance are a matter of investigation.

Indexed as

AllograftsAnimalsBlood DonorsBone Marrow TransplantationDisease Models, AnimalGraft vs Host DiseaseImmune ToleranceMaleMice, Inbred BALB CPhotopheresisT-Lymphocytes, Regulatory

Identifiers

PMID25148404
PMCPMC4141828
OpenAlexW2048767940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.